Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, announced it will deliver an oral presentation on its investigational TNX-801 vaccine platform and lead a working group session at the World Vaccine Congress Europe, taking place October 19-21, 2026, in Amsterdam, Netherlands. The presentation, scheduled for October 21 at 1:15 p.m. CEST, will address the safety and efficacy of TNX-801, a live, attenuated, minimally replicative horsepox virus-based vaccine platform being developed to protect against mpox and other infectious diseases.
The significance of this announcement lies in the potential of TNX-801 to address a critical public health need. Mpox, formerly known as monkeypox, has emerged as a global health concern, with outbreaks occurring in multiple countries. Current vaccines, while effective, have limitations in terms of reactogenicity and accessibility. TNX-801, based on a horsepox virus backbone, is designed to be minimally replicative, which may improve its safety profile while maintaining immunogenicity. If successful, TNX-801 could offer a new tool in the fight against mpox and potentially other infectious diseases, aligning with global efforts to enhance pandemic preparedness.
Tonix's participation in the World Vaccine Congress Europe underscores its commitment to advancing vaccine research. The company will also lead a working group session titled “Vectored Vaccine Platforms: From Design to Improving Efficacy” on October 20 at 11:30 a.m. CEST. This session will bring together experts to discuss the design and optimization of vectored vaccines, a platform technology that TNX-801 exemplifies. By leading this discussion, Tonix positions itself as a thought leader in the vaccine development space, which could enhance its reputation and attract potential collaborators or investors.
For investors, this news matters because it highlights Tonix's pipeline beyond its commercial-stage central nervous system (CNS) products. While Tonix has a marketed portfolio for CNS conditions, including its recently approved flagship medicine TONMYA(TM) for fibromyalgia, and acute migraine products Zembrace(R) SymTouch(R) and Tosymra(R), its immunology programs represent a significant growth opportunity. The advancement of TNX-801, along with other immunology candidates like TNX-4800 for Lyme disease prophylaxis and TNX-1500 for kidney transplant rejection, demonstrates the company's diversified approach to addressing unmet medical needs. Positive developments in these programs could drive long-term value.
The World Vaccine Congress Europe is a prominent event that attracts key stakeholders from the vaccine industry, including researchers, policymakers, and investors. Presenting at this forum allows Tonix to showcase its science to a targeted audience, potentially generating interest and partnerships. The full press release can be viewed at https://ibn.fm/BHVjU, and the latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP.
BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. The platform delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions. For more information, visit BioMedWire or www.BioMedWire.com.
